Cargando…
Potent dual block to HIV-1 infection using lentiviral vectors expressing fusion inhibitor peptide mC46- and Vif-resistant APOBEC3G
Gene therapy strategies that effectively inhibit HIV-1 replication are needed to reduce the requirement for lifelong antiviral therapy and potentially achieve a functional cure. We previously designed self-activating lentiviral vectors that efficiently delivered and expressed a Vif-resistant mutant...
Autores principales: | Delviks-Frankenberry, Krista A., Ojha, Chet R., Hermann, Kip J., Hu, Wei-Shau, Torbett, Bruce E., Pathak, Vinay K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470399/ https://www.ncbi.nlm.nih.gov/pubmed/37662965 http://dx.doi.org/10.1016/j.omtn.2023.08.007 |
Ejemplares similares
-
Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G
por: Delviks-Frankenberry, Krista A., et al.
Publicado: (2019) -
Structural Insights into APOBEC3-Mediated Lentiviral Restriction
por: Delviks-Frankenberry, Krista A., et al.
Publicado: (2020) -
Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation
por: Delviks-Frankenberry, Krista A., et al.
Publicado: (2016) -
Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA
por: Maiti, Atanu, et al.
Publicado: (2018) -
Species‐specific differences in the ability of feline lentiviral Vif to degrade feline APOBEC3 proteins
por: Yoshikawa, Rokusuke, et al.
Publicado: (2016)